

Reinhard Stauder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6699338/publications.pdf>

Version: 2024-02-01

111
papers

7,618
citations

147726

31
h-index

53190

85
g-index

115
all docs

115
docs citations

115
times ranked

6485
citing authors

#	ARTICLE	IF	CITATIONS
1	Multistep pathogenesis of chronic myelomonocytic leukemia in patients. <i>European Journal of Haematology</i> , 2022, , .	1.1	3
2	Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agentsâ€”A Prospective Cohort Study of the AGMT Study-Group. <i>Cancers</i> , 2022, 14, 2459.	1.7	4
3	Updated SIOG COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	2
4	The cancer patientâ€™s perspective of COVIDâ€™19â€™induced distressâ€™A crossâ€™sectional study and a longitudinal comparison of HRQOL assessed before and during the pandemic. <i>Cancer Medicine</i> , 2021, 10, 3928-3937.	1.3	28
5	Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. <i>European Journal of Haematology</i> , 2021, 107, 265-274.	1.1	10
6	The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 848-850.	0.5	11
7	The EHA Research Roadmap: Anemias. <i>HemaSphere</i> , 2021, 5, e607.	1.2	7
8	MRIâ€™Based Iron Phenotyping and Patient Selection for Nextâ€™Generation Sequencing of Nonâ€™Homeostatic Iron Regulator Hemochromatosis Genes. <i>Hepatology</i> , 2021, 74, 2424-2435.	3.6	8
9	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021, 5, 3066-3075.	2.5	12
10	Core Set of Patient-Reported Outcomes for Myelodysplastic Syndromes - EUMDS Delphi Study in Patients and Hematologists. <i>Blood Advances</i> , 2021, , .	2.5	6
11	The anemia-independent impact of myelodysplastic syndromes on health-related quality of life. <i>Annals of Hematology</i> , 2021, 100, 2921-2932.	0.8	7
12	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	2.4	11
13	Is Myelodysplasia a Consequence of Normal Aging?. <i>Current Oncology Reports</i> , 2021, 23, 142.	1.8	5
14	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020, 105, 632-639.	1.7	35
15	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. <i>Haematologica</i> , 2020, 105, 640-651.	1.7	32
16	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. <i>Cancers</i> , 2020, 12, 1891.	1.7	3
17	Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1190-1198.	0.5	60
18	Guideline-based indicators for adult patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2020, 4, 4029-4044.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6057.	1.8	5
20	Geriatric assessment in older patients with a hematologic malignancy: a systematic review. <i>Haematologica</i> , 2020, 105, 1484-1493.	1.7	57
21	Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020, 191, 405-417.	1.2	10
22	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	0.7	2
23	Malnutrition in Older Patients With Hematological Malignancies at Initial Diagnosis – Association With Impairments in Health Status, Systemic Inflammation and Adverse Outcome. <i>HemaSphere</i> , 2020, 4, e332.	1.2	14
24	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	3.3	14
25	Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis. <i>European Journal of Haematology</i> , 2020, 104, 476-487.	1.1	25
26	Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia – A Retrospective Analysis in 337 Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3025.	1.8	11
27	Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age. <i>Haematologica</i> , 2020, 105, 1183-1188.	1.7	46
28	The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent. <i>Journal of Clinical Medicine</i> , 2020, 9, 1005.	1.0	3
29	Comorbidities cluster with impaired functional capacities and depressive mood and predict adverse outcome in older patients with hematological malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 1954-1964.	0.6	6
30	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020, 105, 2516-2523.	1.7	12
31	Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints. <i>Blood</i> , 2020, 136, 29-29.	0.6	2
32	The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML). <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 410-418.	1.0	18
33	Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 497-503.	0.5	22
34	Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group. <i>Blood</i> , 2019, 134, 3821-3821.	0.6	2
35	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	0.6	64
36	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. <i>Leukemia Research</i> , 2018, 67, 21-26.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 115-125.	1.0	0
38	Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. <i>Expert Review of Hematology</i> , 2018, 11, 109-116.	1.0	3
39	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , 2018, 32, 1380-1392.	3.3	66
40	A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1. <i>Leukemia and Lymphoma</i> , 2018, 59, 1121-1126.	0.6	5
41	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). <i>Leukemia and Lymphoma</i> , 2018, 59, 1113-1120.	0.6	23
42	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	2.0	31
43	Anemia at older age: etiologies, clinical implications, and management. <i>Blood</i> , 2018, 131, 505-514.	0.6	266
44	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 547-556.	1.5	3
45	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2018, 2, 2079-2089.	2.5	18
46	A call to action in hematologic disorders: A report from the ASH scientific workshop on hematology and aging. <i>Journal of Geriatric Oncology</i> , 2018, 9, 287-290.	0.5	10
47	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	1.7	49
48	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018, 132, 4357-4357.	0.6	1
49	High Prevalence and Clinical Impact of Malnutrition in Older Patients with a Hematological Malignancy – Basis for Patient Orientated Guidelines and Healthcare Interventions. <i>Blood</i> , 2018, 132, 3532-3532.	0.6	0
50	Deriving Core Patient-Reported Outcomes in Patients with Myelodysplastic Syndromes – a Delphi Survey from the European-MDS Registry. <i>Blood</i> , 2018, 132, 2295-2295.	0.6	0
51	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
52	Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. <i>Annals of Hematology</i> , 2017, 96, 1105-1112.	0.8	11
53	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 837.	1.8	19
54	Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. <i>International Journal of Molecular Sciences</i> , 2017, 18, 415.	1.8	45

#	ARTICLE	IF	CITATIONS
55	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
56	Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. <i>Journal of Hematology and Oncology</i> , 2016, 9, 39.	6.9	36
57	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2016, 128, 3186-3186.	0.6	14
58	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. <i>Haematologica</i> , 2015, 100, 205-213.	1.7	20
59	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 809-817.	1.5	8
60	Validation of the revised international prognostic scoring system (IPSS) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. <i>British Journal of Haematology</i> , 2015, 170, 372-383.	1.2	72
61	Aging and blood disorders: new perspectives, new challenges. <i>Haematologica</i> , 2015, 100, 415-417.	1.7	25
62	Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. <i>Journal of Geriatric Oncology</i> , 2015, 6, 141-152.	0.5	61
63	10th anniversary of the Austrian MDS Platform: aims and ongoing projects. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 12-15.	1.0	1
64	Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management. <i>Drugs and Aging</i> , 2015, 32, 891-905.	1.3	15
65	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	5.1	76
66	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	1.2	59
67	Azacitidine in Acute Myeloid Leukemia with >30% Bone Marrow Blasts and <15 G/L White Blood Cell Count: Results from the Austrian Azacitidine Registry of the AGMT Study Group Versus Randomized Controlled Phase III Clinical Trial Data. <i>Blood</i> , 2015, 126, 2515-2515.	0.6	5
68	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score. <i>Blood</i> , 2015, 126, 2554-2554.	0.6	2
69	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. <i>Blood</i> , 2015, 126, 2861-2861.	0.6	7
70	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 2879-2879.	0.6	1
71	Is It Time to Redefine Response in Elderly Patients with WHO-Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy?. <i>Blood</i> , 2015, 126, 3742-3742.	0.6	3
72	Myelodysplastic Syndromes in Older Patients. , 2015, , 49-61.		0

#	ARTICLE	IF	CITATIONS
73	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , 2015, 126, 2099-2099.	0.6	0
74	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. <i>Blood</i> , 2015, 126, 1677-1677.	0.6	0
75	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, ed39.	0.6	7
76	Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial Registry. <i>Oncologist</i> , 2014, 19, 1069-1075.	1.9	76
77	Anemia in the elderly: clinical implications and new therapeutic concepts. <i>Haematologica</i> , 2014, 99, 1127-1130.	1.7	62
78	PPT and VES-13 in elderly patients with cancer: Evaluation in multidimensional geriatric assessment and prediction of survival. <i>Journal of Geriatric Oncology</i> , 2014, 5, 415-421.	0.5	21
79	Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. <i>Clinical Interventions in Aging</i> , 2014, 9, 1187.	1.3	111
80	Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. <i>Leukemia Research</i> , 2014, 38, 475-483.	0.4	59
81	Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. <i>Journal of Geriatric Oncology</i> , 2014, 5, 299-306.	0.5	24
82	Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. <i>Annals of Hematology</i> , 2014, 93, 1825-1838.	0.8	84
83	Azacitidine in Patients with Treatment-Related Acute Myeloid Leukemia: Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 2284-2284.	0.6	2
84	A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) â€“ AGMT_CMML 1. <i>Blood</i> , 2014, 124, 3268-3268.	0.6	1
85	Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 3681-3681.	0.6	3
86	Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome. <i>Blood</i> , 2014, 124, 3683-3683.	0.6	1
87	Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry. <i>Blood</i> , 2014, 124, 943-943.	0.6	2
88	Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes. <i>Blood</i> , 2014, 124, 955-955.	0.6	26
89	Azacitidine in patients with WHO-defined AML â€“ Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. <i>Journal of Hematology and Oncology</i> , 2013, 6, 32.	6.9	56
90	Complete remission after a single cycle of azacitidine in a case of relapsed acute myeloid leukemia. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 50-53.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013, 122, 2943-2964.	0.6	567
92	Proposed score for survival of patients with myelodysplastic syndromes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1120-1128.	1.7	12
93	Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2013, 122, 2770-2770.	0.6	3
94	The G8 Screening Tool Detects Relevant Geriatric Impairments and Predicts Survival In Elderly Blood Cancer Patients. <i>Blood</i> , 2013, 122, 5209-5209.	0.6	1
95	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. <i>Journal of Clinical Oncology</i> , 2012, 30, 820-829.	0.8	584
96	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	0.6	2,458
97	New developments in MDS. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 186-189.	0.3	0
98	The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. <i>Annals of Hematology</i> , 2012, 91, 1333-1343.	0.8	41
99	Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2012, 120, 3830-3830.	0.6	6
100	Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry. <i>Blood</i> , 2012, 120, 700-700.	0.6	2
101	Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. <i>Journal of Clinical Oncology</i> , 2011, 29, 1963-1970.	0.8	139
102	Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. <i>Blood</i> , 2011, 118, 1715-1715.	0.6	2
103	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. <i>Blood</i> , 2011, 118, 2775-2775.	0.6	20
104	Report on Response and Overall Survival of 128 Unselected, Consecutive AML Patients From the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group. <i>Blood</i> , 2011, 118, 4266-4266.	0.6	0
105	Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry. <i>Blood</i> , 2010, 116, 2917-2917.	0.6	5
106	Myelodysplastic syndromes (MDS). <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 108-109.	0.3	0
107	Impact of Age and Comorbidity in Myelodysplastic Syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008, 6, 927-934.	2.3	37
108	New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. <i>Blood</i> , 2007, 110, 4385-4395.	0.6	719

#	ARTICLE	IF	CITATIONS
109	Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications. <i>Leukemia and Lymphoma</i> , 2007, 48, 1900-1909.	0.6	21
110	Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. <i>Clinical Leukemia</i> , 2007, 1, 353-356.	0.2	7
111	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. <i>Leukemia Research</i> , 2007, 31, 727-736.	0.4	478